- Atossa Therapeutics (ATOS, Financial) secures a new U.S. patent for enteric oral formulations of (Z)-endoxifen.
- This patent strengthens Atossa's intellectual property estate, covering over 100 claims for (Z)-endoxifen formulations.
- The development enhances Atossa's position in breast cancer treatment, focusing on hormone-dependent disorders.
Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company, has announced the issuance of U.S. Patent No. 12,275,684 by the United States Patent and Trademark Office (USPTO). This patent is directed towards enteric oral formulations of (Z)-endoxifen and their use in treating hormone-dependent breast and reproductive tract disorders.
This latest addition reinforces Atossa's intellectual property portfolio, which already includes multiple patents with over 100 claims related to (Z)-endoxifen formulations and their clinical applications. The enteric oral formulations covered by the patent offer a strategic advantage by potentially extending market exclusivity for these targeted therapies.
Atossa's President and CEO, Dr. Steven Quay, commented that the issuance of this patent marks a significant milestone in advancing their mission to develop innovative treatments for breast cancer. By fortifying their intellectual property holdings, Atossa aims to provide effective therapeutic options for patients with hormone receptor-positive breast cancer.
(Z)-endoxifen, the company's lead product candidate, is a potent Selective Estrogen Receptor Modulator (SERM), showcasing efficacy in patients resistant to other hormonal treatments. Atossa is actively developing this compound for various applications, including prevention, neoadjuvant, adjuvant, and metastatic breast cancer settings.
The new patent does not alter the clinical timelines for Atossa's breast cancer program but enhances the commercial potential if clinical development proves successful. Atossa remains committed to rigorous clinical research and developing patient-centered solutions to meet the unmet medical needs in breast cancer treatment and prevention.
